Literature DB >> 1569060

Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells.

T Hironaka1, K Furukawa, P C Esmon, M A Fournel, S Sawada, M Kato, T Minaga, A Kobata.   

Abstract

The asparagine-linked sugar chains of blood coagulation factor VIII preparations purified from human plasma of blood group A donors and from the culture media of recombinant BHK cells were released as oligosaccharides by hydrazinolysis. These sugar chains were converted to radioactive oligosaccharides by reduction with sodium borotritide and separated into neutral and acidic fractions by paper electrophoresis. Most of the acidic oligosaccharides were converted to neutral ones by sialidase digestion, indicating that they are sialyl derivatives. The neutral and sialidase-treated acidic oligosaccharides were fractionated by serial chromatography on immobilized lectin columns and Bio-Gel P-4 column. Structural study of each oligosaccharide by sequential exo- and endoglycosidase digestion and by methylation analysis revealed that both factor VIII preparations contain mainly high mannose-type and bi-, tri-, and tetra-antennary complex-type sugar chains. Some of the biantennary complex-type sugar chains from human plasma factor VIII contain blood group A and/or H determinant, while those from recombinant product do not. Some of the bi-, tri- and tetra-antennary complex-type sugar chains of the recombinant factor VIII contain the Gal alpha 1----3Gal group. A small number of the triantennary complex-type sugar chains from both preparations was found to contain the Gal beta 1----4(Fuc alpha 1----3)GlcNAc beta 1----4 (Gal beta 1----4GlcNAc beta 1----2)Man group. Studies of pharmacokinetic parameters of the recombinant factor VIII infused into baboons revealed that its half-life in blood circulation is similar to that of plasma derived factor VIII, suggesting that the oligosaccharide structural differences between them do not affect the fate of factor VIII in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569060

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  IgG Antibodies Against Factor VIII in Normal Individuals.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Present and future challanges in the treatment of haemophilia: a clinician's perspective.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

3.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

Review 4.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

5.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

6.  Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.

Authors:  Julie N Pegon; Mohamad Kurdi; Caterina Casari; Soline Odouard; Cécile V Denis; Olivier D Christophe; Peter J Lenting
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

7.  Lectin binding assays for in-process monitoring of sialylation in protein production.

Authors:  Weiduan Xu; Jianmin Chen; Glenn Yamasaki; John E Murphy; Baisong Mei
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

8.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 9.  Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.

Authors:  U Galili
Journal:  Springer Semin Immunopathol       Date:  1993

Review 10.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.